MIF and neoplasm: In terms of promoting tumor drug resistance, TA-MSCs, TA-MSCs-EVs and MIF can promote tumor drug resistance by activating the same signaling pathway and regulating similar related protein expression, such as STAT3, MAPK, Bcl etc.